. "Minocycline"@en . . . . . . . . . . . . . . . . . . . . . . . "investigational"@en . . . . . " "@en . . . . . . . . . . . . . . . "Take with food."@en . . . . . . . . . . . . . . . . "Zita Mendes, Jose Rafael Antunes, Susana Marto, William Heggie, \"Crystalline Minocycline Base and Processes for its Preparation.\" U.S. Patent US20100286417, issued November 11, 2010."@en . . . . . . . . . . . . . . . . . . . "Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%."@en . . . . . . . . . . "For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniae and for the treatment of asymptomatic carriers of Neisseria meningitidis."@en . . . . . . "Minociclinum"@en . . . . . . . . . "10118-90-8"@en . . . . . . . . . "Minocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD₅₀=2380 mg/kg (rat, oral), LD₅₀=3600 mg/kg (mouse, oral)"@en . "55% to 76%"@en . . . . . "Minocyclin"@en . "Do not take Aluminum or magnesium antacids or supplements while on this medication."@en . . . . . . . . . . . . . . . "Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis."@en . . . "Minocyclinum"@en . . . "Calcium and iron needs increased with long term use."@en . "Enteric bacteria and other eubacteria"@en . . . "11-22 hours"@en . . . . . . . . . . . "Minociclina"@en . "(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide"@en . "approved"@en . . . . . . . . . . . . . . . . . . . "A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem]"@en . . "# \"Link\":http://en.wikipedia.org/wiki/Minocycline # \"Link\":http://www.medsafe.govt.nz/profs/Datasheet/m/Minotabtab.htm # Gough A, Chapman S, Wagstaff K, Emery P, Elias E: Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996 Jan 20;312(7024):169-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8563540 # Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10888929 # Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001 Jun 15;166(12):7527-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11390507 # Nirmalananthan N, Greensmith L: Amyotrophic lateral sclerosis: recent advances and future therapies. Curr Opin Neurol. 2005 Dec;18(6):712-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16280684 # Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15371729"@en . . . "7-Dimethylamino-6-demethyl-6-deoxytetracycline"@en . . . . . . . . " "@en . . . . . . . . . . . . . . . . . . . . .